Publications by authors named "Craig Gedye"

Claim this Profile
F
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.
Martin H Voss, Howard Gurney, Vagif Atduev, Cristina Suarez, Miguel A Climent, Craig Gedye

Eur Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.
Andrew J Armstrong, Fred Saad, Mototsugu Oya, Karina Vianna, Mustafa Özgüroğlu, Craig Gedye

Eur Urol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and derived macrophages occupy distinct phenotypic states.
Stéphane Chevrier, Vito R T Zanotelli, Daniel Schulz, Mark D Robinson, Laurie Ailles, Craig Gedye

bioRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, David Pook, Christopher M Hocking, Craig Gedye

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Support Participants in Urogenital and Prostate Clinical Trials: A Qualitative Perspective.
Natasha A Roberts, Ian D Davis, David Wyld, Jeffrey Goh, Maxwell Thompson, Craig Gedye

Psychooncology· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M Joshua, Shahneen Sandhu, Craig Gedye

Lancet Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant immunotherapy for high-risk renal cell carcinoma-now or never?
Tivya Kulasegaran, Niara Oliveira, Craig Gedye, Shomik Sengupta

BJU Int· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
Fred Saad, Andrew J Armstrong, Mototsugu Oya, Karina Vianna, Mustafa Özgüroğlu, Craig Gedye

Eur Urol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.
Cora N Sternberg, Yohann Loriot, Ernest Choy, Daniel Castellano, Fernando Lopez-Rios, Craig Gedye

Eur Urol Focus· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
Peter Grimison, Antony Mersiades, Adrienne Kirby, Annette Tognela, Ian Olver, Craig Gedye

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, James Larkin, Tom Powles, Craig Gedye

Contemp Clin Trials Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).
Primo N Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Craig Gedye

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Craig Gedye

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
Ciara Conduit, Ian D Davis, Jeffrey C Goh, Ganessan Kichenadasse, Howard Gurney, Craig Gedye

BJU Int· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival with [Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James P Buteau, Craig Gedye

Lancet Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.
Hao-Wen Sim, Luke Wachsmuth, Elizabeth H Barnes, Sonia Yip, Eng-Siew Koh, Craig Gedye

Neurooncol Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Laurence Albiges, Howard Gurney, Vagif Atduev, Cristina Suarez, Miguel A Climent, Craig Gedye

Lancet Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy.
Amiee Dowdell, Mark Marsland, Sam Faulkner, Craig Gedye, James Lynam

FASEB Bioadv· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Membrane Protein Sortilin Is a Potential Biomarker and Target for Glioblastoma.
Mark Marsland, Amiee Dowdell, Sam Faulkner, Craig Gedye, James Lynam

Cancers (Basel)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Louise Emmett, Nikeith John, Sarennya Pathmanandavel, William Counter, Maria Ayers, Craig Gedye

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Andrew B Lassman, Stephanie L Pugh, Tony J C Wang, Kenneth Aldape, Hui K Gan, Craig Gedye

Neuro Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Mark Marsland, Amiee Dowdell, Sam Faulkner, Phillip Jobling, Robert A Rush, Craig Gedye

Int J Mol Sci· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group).
Fiona Day, Swetha Sridharan, James Lynam, Craig Gedye, Catherine Johnson

BMC Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma.
Benjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, Anna K Nowak, Elizabeth J Hovey, Craig Gedye

BMJ Open· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, Nobuaki Matsubara, Niven Mehra, Craig Gedye

Eur J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis